Skip to main content

Table 2 Baseline patient characteristics

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Characteristic

Median [range] or No. (%)

Age, years

72 [17–85]

Male gender

28 (61)

ECOG status

 

  0

16 (35)

  1

23 (50)

  2

6 (13)

  Unknown

1 (2)

Time since diagnosis, years

2.9 [0–21]

Number of prior systemic therapies

3 [19]

Prior ASCT

16 (35)

Diagnosis after confirmatory review

 

  DLBCL

40 (87)

  Follicular NHL (grade 2)

3 (7)

  Marginal zone

2 (4)

  Diffuse large cell NHL, lineage undetermined

1 (2)

DLBCL subtype

 

  GCB

14 (30)

  Non-GCB

14 (30)

  Missing

18 (39)

CD40 staining intensity

 

  0

1 (2)

  1+

2 (4)

  2+

13 (28)

  3+

25 (54)

  Not available

5 (11)

  1. ECOG, Eastern Cooperative Oncology Group; ASCT, autologous stem cell transplantation; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell; NHL, non-Hodgkin lymphoma.